NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
JS InnoPharm, LLC
DNAtrix, Inc.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
University of Lausanne Hospitals